Navigation Links
Ionian Technologies, Inc. Receives Additional Funding from the Bill & Melinda Gates Foundation to Develop Point-of-Care Diagnostic Tests for the Developing World
Date:11/18/2009

SAN DIEGO, Nov. 18 /PRNewswire/ -- Ionian Technologies, Inc., will continue its efforts to develop a rapid point-of-care diagnostics platform for use in the developing world with supplemental funding from the Bill & Melinda Gates Foundation. This grant from the Foundation will extend the total commitment to this program, which was initiated in November 2008, to $3 million over two years.

The program will continue to focus on utilizing Ionian's proprietary isothermal nucleic acid amplification technology, the NEAR Assay, to develop a platform for various global health diseases that will uniquely meet the needs of diagnostics for use in the developing world. The initial diseases that will be targeted are tuberculosis, chlamydia, and gonorrhea. However, the platform will be easily adapted to other priority global health diseases in subsequent efforts.

The NEAR Assay can detect either DNA or RNA from bacterial or viral pathogens with a five-minute amplification coupled with a simple and rapid detection by fluorescence or lateral-flow test strips. The power of the NEAR amplification reaction matches the sensitivity and specificity performance of the best current nucleic acid technologies such as PCR, but in less time and with a much less complicated handheld device. Additionally, the NEAR Assay requires minimal or no sample preparation, further simplifying the equipment and consumable test requirements. These key attributes enable highly affordable and portable diagnostics for the most remote applications throughout the developing world.

Founded in 2000, Ionian Technologies, Inc. is focused on commercializing its proprietary technology for the rapid detection of nucleic acids in various fields, including human in vitro diagnostics, food safety, biodefense, agriculture, and veterinary applications. Ionian is privately held and is based in San Diego, CA.

SOURCE Ionian Technologies, Inc.


'/>"/>
SOURCE Ionian Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ionian Technologies, Inc. Signs Molecular Diagnostic Manufacturing Agreement With Roche Diagnostics
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
6. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Wound Management Technologies, Inc. Announces Evidence Based Study
10. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
11. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/27/2017)... (PRWEB) , ... May 26, 2017 , ... A May ... who visit a doctor for colds or respiratory issues that are not responsive to ... time pressure on doctors may be largely responsible for the problem both in Canada ...
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... to review more than eighty-nine grant submissions all vying for nearly $1,000,000 in ... the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Amir Qureshi, ... System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System ... “We are pleased to be the first in Arkansas to introduce the most powerful ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
Breaking Medicine News(10 mins):